Ivarmacitinib
As of the edition of 20 October 2026, Ivarmacitinib is a small molecule: stopped in 2026; acts on JAK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 35, 1 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Cancer; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| JAK1 | Tyrosine-protein kinase JAK1 | P23458 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 3 | 0 |
| Phase 1 | 13 | 9 | 0 | 0 |
| Phase 2 | 12 | 3 | 8 | 1 |
| Phase 3 | 5 | 2 | 1 | 0 |
| Phase 4 | 2 | 0 | 2 | 0 |
| All trials | 35 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2015 to now |
| Reistone Biopharma | Lead sponsor of trials | 2019 to now |